布地奈德福莫特罗粉吸入剂联合孟鲁司特钠治疗咳嗽变异性哮喘临床观察

2017-04-18 13:19:43陈波勇姜仁早何淑梅
中国实用医药 2017年8期

陈波勇+姜仁早+何淑梅

【摘要】 目的 探讨布地奈德福莫特罗粉吸入剂联合孟鲁司特钠在咳嗽变异性哮喘(CVA)患者中治疗效果。方法 80例CVA患者为研究对象, 采用信封分组法将患者分为A组和B组, 各40例。A组在B组单用布地奈德福莫特罗粉吸入剂基础上联合孟鲁司特钠治疗, 两组患者连续治疗2个月, 比较两组患者疗效及治疗前后咳嗽症状评分、咳嗽生活质量(采用LCQ问卷评价)及外周血免疫球蛋白E(IgE)水平。结果 A组患者临床治疗总有效率为97.50%, 明显高于B组的85.00%, 差异具有统计学意义(P<0.05)。治疗前两组患者咳嗽症状评分、LCQ评分及IgE水平比较差异无统计学意义(P>0.05);治疗后两组患者咳嗽症状、LCQ评分及IgE水平较治疗前均有显著改善, A组患者改善程度较B组更显著, 差异具有统计学意义(P<0.05)。结论 布地奈德福莫特罗粉吸入剂联合孟鲁司特钠在CVA中治疗较单用布地奈德福莫特罗粉吸入剂吸入治疗效果更为显著, 但可增加患者治疗经济负担, 临床中应根据患者整体情况合理用药, 以获得显著临床疗效和患者治疗满意度。

【关键词】 布地奈德福莫特罗粉吸入剂;孟鲁司特钠;咳嗽变异性哮喘

DOI:10.14163/j.cnki.11-5547/r.2017.08.056

【Abstract】 Objective To investigate curative effect by budesonide formoterol powder inhalation combined with montelukast sodium in the treatment of cough variant asthma (CVA). Methods A total of 80 CVA patients as study subjects were divided by envelope method into group A and group B, with 40 cases in each group. Group B received budesonide formoterol powder inhalation, and group A received additional montelukast sodium for combined treatment. Their treatment all lasted for 2 months. Comparison was made on curative effects, cough symptom score, cough quality of life (Leicester cough questionnaire, LCQ) and peripheral blood immunoglobulin E (IgE) level between the two groups before and after treatment. Results Group A had obviously higher total effective rate in clinical treatment as 97.50% than 85.00%, and their difference had statistical significance (P<0.05). There was no statistically significant difference cough symptom score, LCQ score and IgE level between the two groups before treatment (P>0.05). After treatment, both groups had obvious improvements in cough symptom score, LCQ score and IgE level, and group A had much better improvement than group B. Their difference had statistical significance (P<0.05). Conclusion Combination of budesonide formoterol powder inhalation and montelukast sodium provides more remarkable curative effect in treating CVA than single implement of budesonide formoterol powder inhalation, but this method increase financial burden in treatment. Rational clinical medication in accordance with patients condition is necessary to provide excellent clinical effect and treatment satisfaction.

【Key words】 Budesonide formoterol powder inhalation; Montelukast sodium; Cough variant asthma

CVA為哮喘中特殊疾病类型之一, 以气道高反应为病理特征, 表现为慢性咳嗽、喘息, 对患者健康和生活质量均造成严重影响。长期呼吸道吸入解痉平喘药物为控制症状关键, 布地奈德福莫特罗粉吸入剂为新型混合型吸入药物, 吸入后在气道内局部具有较强抗炎、扩张支气管作用, 全身副作用较小, 在临床中治疗哮喘常用药物[1-6]。为探究布地奈德福莫特罗粉吸入剂联合孟鲁司特钠在CVA中治疗效果, 作者研究如下。

1 资料与方法

1. 1 一般资料 选取2014年6月~2016年6月本院哮喘门诊就诊的80例CVA患者为研究对象, 采用信封分组法将患者分为A组和B组, 每组40例。根据患者病史、临床表现、体征, 结合肺功能、支气管舒张实验检查, 明确诊断为CVA;……

登录APP查看全文